期刊
MICROBIAL DRUG RESISTANCE
卷 24, 期 5, 页码 519-526出版社
MARY ANN LIEBERT, INC
DOI: 10.1089/mdr.2017.0279
关键词
tigecycline; MRSA; MepR; MepA
资金
- Sao Paulo Research Foundation [FAPESP 2010/02619-0, FAPESP 2013/24952-0]
- Coordination for the Improvement of Higher Education Personnel [CAPES/PVE 88881.030524/2013-01, CAPES 88887.114824/2015-00]
- National Institutes of Health (DHHS/NIH/NIAID) [AI072360, AI083214, AI109855]
- NATIONAL EYE INSTITUTE [K99EY028222] Funding Source: NIH RePORTER
- NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P01AI083214] Funding Source: NIH RePORTER
A tigecycline-susceptible (TGC-S) Sequence Type (ST) 5 clinical methicillin-resistant Staphylococcus aureus (MRSA) strain was cultured in escalating levels of tigecycline, yielding mutants eightfold more resistant. Their genomes were sequenced to identify genetic alterations, resulting in resistance. Alterations in rpsJ, commonly related to tigecycline resistance, were also investigated. Tigecycline resistance was mediated by loss-of-function mutations in the transcriptional repressor mepR, resulting in derepression of the efflux pump mepA. Increased levels of resistance were obtained by successive mutations in mepA itself. No alterations in RpsJ were observed in selected strains, but we observed a K57M substitution, previously correlated with resistance, among TGC-S clinical strains. Thus, the pathway to tigecycline resistance in CC5 MRSA in vitro appears to be derepression of mep operon as the result of mepR loss-of-function mutation, followed by alterations in MepA efflux pump. This shows that other evolutionary pathways, besides mutation of rpsJ, are available for evolving tigecycline resistance in CC5 MRSA.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据